PeptideNerds

Mazdutide

GLP-1 / Weight Loss Clinical Trials moderate evidence Track This Protocol
Alejandro Reyes

Written by Alejandro Reyes

Founder & Lead Researcher

PN

Reviewed by Peptide Nerds Editorial · Updated April 2026

Key Takeaway

Mazdutide is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics, primarily studied in Chinese populations.

Quick Facts
Type GLP-1 / Weight Loss
FDA Status Clinical Trials
Evidence Level Moderate
Typical Dose 3 mg to 9 mg weekly
Frequency Once weekly
Key Goals weight-loss

How it works

Dual GLP-1 and glucagon receptor agonism for appetite suppression and increased energy expenditure.

Benefits

  • Significant weight loss in Phase 3 trials
  • Improved metabolic markers

Side effects

  • Nausea
  • Diarrhea
  • GI side effects similar to other GLP-1 agonists

Dosing protocol

Typical Dose

3 mg to 9 mg weekly

Frequency

Once weekly

Approved in China. Not yet available in the US.

Deeper on Mazdutide

Full breakdowns of every part of the Mazdutide research base.

What you will need

Basic supplies for reconstitution and subcutaneous injection.

This page contains affiliate links. Learn more

Get the Mazdutide cheat sheet

Dosing quick-reference, key studies, and side effect management — in your inbox.

Get the Mazdutide cheat sheet

Dosing quick-reference, key studies, and side effect management — in your inbox.

Related peptides

Get the Peptide Starter Kit (free)

Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.

Medical Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol.